Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, Hennessy B, Sidorenko T, Vaclavkova A, Olsson T; Ponesimod Phase II Study Group. Freedman MS, et al. Among authors: sidorenko t. Neurology. 2022 Aug 23;99(8):e762-e774. doi: 10.1212/WNL.0000000000200606. Epub 2022 Jun 6. Neurology. 2022. PMID: 35667837 Free PMC article. Clinical Trial.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Olsson T, et al. Among authors: sidorenko t. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. J Neurol Neurosurg Psychiatry. 2014. PMID: 24659797 Free PMC article. Clinical Trial.
An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
Valenzuela B, Olsson Gisleskog P, Poggesi I, Sidorenko T, Burcklen M, Kracker H, Pérez-Ruixo JJ. Valenzuela B, et al. Among authors: sidorenko t. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1294-1304. doi: 10.1002/psp4.12778. Epub 2022 Sep 1. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36047474 Free PMC article. Clinical Trial.
Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
Tervonen T, Fox RJ, Brooks A, Sidorenko T, Boyanova N, Levitan B, Hennessy B, Phillips-Beyer A. Tervonen T, et al. Among authors: sidorenko t. Mult Scler J Exp Transl Clin. 2023 Jan 23;9(1):20552173221150370. doi: 10.1177/20552173221150370. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36714174 Free PMC article.
[Pathogenetic treatment of multiple sclerosis: the present and the future].
Boĭko AN, Stoliarov ID, Sidorenko TV, Kulakova OV, Kol'iak EV, Petrov AM, Il'ves AG, Nikiforova IG, Favorova OO, Gusev EI. Boĭko AN, et al. Among authors: sidorenko tv. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):90-9. Zh Nevrol Psikhiatr Im S S Korsakova. 2009. PMID: 19894313 Review. Russian.
[Data of MRI and neuropsychological tests predict the course of typical remitting multiple sclerosis during five years].
Mugutdinova BT, Boĭko AN, Serkov SV, Fadeeva LM, Enikolopova EV, Bogolepova AN, Lashch NIu, Davydovskaia MF, Khachanova NV, Popova NF, Shchur SG, Riabukhina OV, Romashkin AV, Sidorenko TV, Gusev EI. Mugutdinova BT, et al. Among authors: sidorenko tv. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):29-37. Zh Nevrol Psikhiatr Im S S Korsakova. 2011. PMID: 21919232 Russian.
[Adherence to long-term therapy with disease modifying drugs].
Sidorenko TV, Boĭko AN, Davydovskaia MF, Zolotova SN, Lash NIu, Popova NF, Khachanova NV, Shur SG, Gusev EI. Sidorenko TV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):107-13. Zh Nevrol Psikhiatr Im S S Korsakova. 2009. PMID: 19891354 Russian.
27 results